Study evaluates the benefits of ocrelizumab on 48-week confirmed disability progression in MS observed in pooled OPERA I and OPERA II, as well as a 3 year ocrelizumab treatment in an open-label extension.
Study demonstrated efficacy in improving communication with the clinician, lowering the number of visits, and improving the coordination of single-day multi-service and therapeutic interventions in multiple sclerosis
The investigators of this Phase 3 study sought to evaluate the efficacy and safety of ADS-5102 (amantadine) extended-release capsules to treat multiple sclerosis patients with walking impairment.
Investigators sought to determine the safety and efficacy of twice-daily dosing of arbaclofen ER in patients with spasticity due to multiple sclerosis.
Age- and sex-stratified comorbidity and concomitant medication use has been found among individuals with MS who have newly initiated disease-modifying drugs.
Despite the occurrence of thyroid adverse events or their severity, AEs had a minimal impact on quality of life for patients with relapsing-remitting multiple sclerosis who had been treated with alemtuzumab.
Investigators examine the use treatment patterns and utilization of disease-modifying therapy in newly diagnosed pediatric patients with multiple sclerosis.
The investigators of this study sought to evaluate the long-term efficacy and safety of alemtuzumab to treat patients of African descent who have relapsing-remitting MS.
Nonadherence to once- or twice-daily oral disease-modifying drugs among individuals with multiple sclerosis is associated with considerable resource use and economic and clinical burden.
A 15-minute continuing medical education video improved knowledge among neurologists and primary care physicians related to managing multiple sclerosis prior to and during pregnancy.
